The chief researcher of an Israeli study on the administration of a fourth dose of the Covid-19 vaccine believes that the results – the five-fold increase in antibodies – are “good but not enough”. “There is an increase, but it is not really impressive,” said Professor Gili Regev on Wednesday. Shortly following the fourth dose, the antibody level returns to the level it had just following the third. The researchers hoped for more. Professor Regev believes that it is a good thing that vulnerable groups like the immunocompromised or those over 60 can have access to a second booster dose in Israel. “But I’m not sure it should be given to everyone. We need more information.”
Another study on the administration of the fourth dose began on Wednesday at a hospital in Tel Aviv.
